LONDON—The Covid-19 vaccine being developed by the University of Oxford and AstraZeneca PLC was found to be as much as 90% effective in preventing infections without serious side effects in a large clinical trial in the U.K. and Brazil, the partners said Monday.
Efficacy ranged from 62% to 90% depending on dosage given, AstraZeneca and Oxford said.
AstraZeneca…
This post first appeared on wsj.com
